T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Lam Research
LRCX
|
+$1.66B |
| 2 |
KLA
KLAC
|
+$1.39B |
| 3 |
T-Mobile US
TMUS
|
+$1.38B |
| 4 |
Eli Lilly
LLY
|
+$1.37B |
| 5 |
CSX Corp
CSX
|
+$1.18B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$4.2B |
| 2 |
Microsoft
MSFT
|
+$3.24B |
| 3 |
Amazon
AMZN
|
+$2.75B |
| 4 |
Netflix
NFLX
|
+$2.53B |
| 5 |
Apple
AAPL
|
+$2.48B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 35.66% |
| 2 | Financials | 11.78% |
| 3 | Healthcare | 11.44% |
| 4 | Consumer Discretionary | 10.75% |
| 5 | Communication Services | 10.73% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
776
Xometry
XMTR
$5.42B
| $56.7M | 0.01% |
952,796
-11,894
| -1% | -$670K |
|
|
VSXY
777
Victoria's Secret
VSXY
$7.24B
| $56.6M | 0.01% |
1,045,465
+978,194
| +1,454% | +$38.9M |
|
778
Itron
ITRI
$4.5B
| $56.5M | 0.01% |
607,941
-123,542
| -17% | -$13.5M |
|
779
Brink's
BCO
$4.72B
| $56.3M | 0.01% |
482,414
-490
| -0.1% | -$56K |
|
780
SBA Communications
SBAC
$19.8B
| $56.3M | 0.01% |
291,016
-95,144
| -25% | -$18.4M |
|
781
Copart
CPRT
$27.2B
| $56.2M | 0.01% |
1,434,356
-218,768
| -13% | -$9.07M |
|
782
UMB Financial
UMBF
$11.5B
| $55.9M | 0.01% |
486,066
+238,173
| +96% | +$27M |
|
783
Arrowhead Research
ARWR
$12.1B
| $55.7M | 0.01% |
838,818
+728,573
| +661% | +$35.7M |
|
784
Kilroy Realty
KRC
$4.3B
| $55.6M | 0.01% |
1,487,767
-219,136
| -13% | -$8.96M |
|
785
Kroger
KR
$35.1B
| $55.4M | 0.01% |
887,413
+2,700
| +0.3% | +$177K |
|
786
Celldex Therapeutics
CLDX
$3.35B
| $55.4M | 0.01% |
2,039,705
-342,813
| -14% | -$9.03M |
|
787
The Bancorp
TBBK
$2.82B
| $54.6M | 0.01% |
808,185
-46,747
| -5% | -$3.23M |
|
788
Boston Properties
BXP
$11B
| $54.6M | 0.01% |
808,659
-18,444
| -2% | -$1.31M |
|
789
AST SpaceMobile
ASTS
$21.4B
| $54.6M | 0.01% |
751,170
+211,385
| +39% | +$15.1M |
|
790
Kadant
KAI
$3.91B
| $54.4M | 0.01% |
190,951
+539
| +0.3% | +$153K |
|
791
Lantheus
LNTH
$6.59B
| $54.4M | 0.01% |
817,247
+5,337
| +0.7% | +$311K |
|
792
Vaxcyte
PCVX
$8.76B
| $54.2M | 0.01% |
1,175,339
-513,144
| -30% | -$23M |
|
793
Kratos Defense & Security Solutions
KTOS
$11.8B
| $54.1M | 0.01% |
712,620
-1,342,438
| -65% | -$110M |
|
794
AeroVironment
AVAV
$9.59B
| $54M | 0.01% |
223,255
-16,386
| -7% | -$5.15M |
|
795
Dollar General
DG
$26.9B
| $53.9M | 0.01% |
405,633
-655,987
| -62% | -$73.2M |
|
796
WEC Energy
WEC
$35.9B
| $53.8M | 0.01% |
510,603
+2,151
| +0.4% | +$238K |
|
797
GeneDx Holdings
WGS
$2.36B
| $53.8M | 0.01% |
413,991
+82,583
| +25% | +$11.3M |
|
798
FormFactor
FORM
$10.3B
| $53.8M | 0.01% |
964,578
+308,826
| +47% | +$15.6M |
|
799
Gen Digital
GEN
$17.7B
| $53.7M | 0.01% |
1,973,539
+593,189
| +43% | +$16M |
|
800
ACI Worldwide
ACIW
$5.42B
| $53.1M | 0.01% |
1,111,538
+50,694
| +5% | +$2.46M |
|
Similar funds
T. Rowe Price Associates's Q4 2025 Portfolio in Review
As of Q4 2025, T. Rowe Price Associates held 3,154 positions worth $927B, down 0.78% from $935B the previous quarter. Its ten largest holdings account for 37% of the portfolio.
T. Rowe Price Associates's Q4 2025 filing shows 113 new, 1,841 increased, 860 reduced and 65 closed positions. Its largest new stake was Medline Inc: 7,325,104 shares worth $308M. The largest sale was NVIDIA, an estimated $4.2B.
By sector, the portfolio is most concentrated in Technology at 36% of assets, down from 36% a quarter earlier, followed by Financials and Healthcare.
- T. Rowe Price Associates's largest Q4 2025 buy was Medline Inc: 7,325,104 shares worth $308M.
- T. Rowe Price Associates added most to Lam Research in Q4 2025, an estimated $1.66B increase.
- T. Rowe Price Associates's biggest Q4 2025 reduction was NVIDIA, cutting an estimated $4.2B.
- T. Rowe Price Associates fully exited Akero Therapeutics in Q4 2025, selling an estimated $181M.
- T. Rowe Price Associates's ten largest holdings make up 37% of its $927B portfolio in Q4 2025.
- T. Rowe Price Associates opened 113 new positions and closed 65 in Q4 2025.
- T. Rowe Price Associates's portfolio value fell 0.78% quarter-over-quarter to $927B.
Based on T. Rowe Price Associates's 13F filing for Q4 2025, filed 17 Feb 2026.